COMMON STOCK PURCHASE WARRANT SCILEX HOLDING COMPANYCommon Stock Purchase Warrant • March 5th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on March 5, 2029 (the “Termination Date”), to subscribe for and purchase from Scilex Holding Company, a Delaware corporation (the “Company”), up to ______ shares of the Company’s Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 25th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 23, 2024, between Scilex Holding Company, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 26th, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances)
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and Purchaser (the “Purchase Agreement”).
12,000,000 Units Vickers Vantage Corp. I UNDERWRITING AGREEMENTUnderwriting Agreement • January 11th, 2021 • Vickers Vantage Corp. I • Blank checks • New York
The undersigned, Vickers Vantage Corp. I, a Cayman Islands exempted company (“Company”), hereby confirms its agreement with Maxim Group LLC (hereinafter referred to as “you”, “Maxim”, or as the “Representative”) and with the other underwriters named on Schedule A hereto for which you are acting as representative (the Representative and the other Underwriters being collectively referred to herein as the “Underwriters” or, individually, an “Underwriter”), as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 11th, 2021 • Vickers Vantage Corp. I • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of January 6, 2021, by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (the “Company”), and the undersigned parties listed under Investors on the signature page hereto (each, an “Investor” and collectively, the “Investors”).
SCILEX HOLDING COMPANY Shares of Common Stock (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • July 13th, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
Scilex Holding Company, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of shares of its common stock, par value $0.0001 per share (the “Shares”). The Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional Shares. The additional Shares to be sold by the Company pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean
INDEMNIFICATION AGREEMENTIndemnification Agreement • November 17th, 2022 • Scilex Holding Company/De • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between Scilex Holding Company, a Delaware corporation (the “Company”), and (“Indemnitee”).
COMMON STOCK PURCHASE WARRANT SCILEX HOLDING COMPANYCommon Stock Purchase Warrant • April 25th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 25, 2029 (the “Termination Date”), to subscribe for and purchase from Scilex Holding Company, a Delaware corporation (the “Company”), up to ______ shares of the Company’s Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 8th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2024, is by and among Scilex Holding Company, a Delaware corporation with offices located at 960 San Antonio Road, Palo Alto, CA 94303 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”) and Acquiom Agency Services LLC as collateral agent (the “Collateral Agent”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • January 11th, 2021 • Vickers Vantage Corp. I • Blank checks • New York
This Agreement, made and entered into effective as of January 6, 2020 (“Agreement”), by and between Vickers Vantage Corp. I, a Cayman Islands exempted company (“Company”), and the undersigned indemnitee (“Indemnitee”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • January 11th, 2021 • Vickers Vantage Corp. I • Blank checks • New York
This Investment Management Trust Agreement (this “Agreement”) is made as of January 6, 2021 by and between Vickers Vantage Corp. I (the “Company”) and Continental Stock Transfer & Trust Company (“Trustee”).
SCILEX HOLDING COMPANY COMMON STOCK SALES AGREEMENTSales Agreement • December 22nd, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
AMENDED AND RESTATED STANDBY EQUITY PURCHASE AGREEMENTStandby Equity Purchase Agreement • February 9th, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”), dated as of February 8, 2023 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and SCILEX HOLDING COMPANY, a company incorporated under the laws of the State of Delaware (the “Company”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 21st, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances)
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 21, 2023 by and among SCILEX HOLDING COMPANY, INC., a Delaware corporation (the “Company”), and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the “Investor”).
UNDERWRITER COMMON STOCK PURCHASE WARRANT SCILEX HOLDING COMPANYUnderwriter Common Stock Purchase Warrant • March 5th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on March 5, 2029 (the “Termination Date”), to subscribe for and purchase from Scilex Holding Company, a Delaware corporation (the “Company”), up to ______ shares of the Company’s Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to the Underwriting Agreement (as defined herein) and the Engagement Letter, by and between the Company and StockBlock Securities LLC, dated as of February 29, 2024.
Vickers Vantage Corp. I New York, NY 10004 Maxim Group LLC New York, NY 10174Underwriting Agreement • December 15th, 2020 • Vickers Vantage Corp. I • Blank checks • New York
This letter (“Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Vickers Vantage Corp. I, a Delaware corporation (the “Company”), and Maxim Group LLC as representative (the “Representative”) of the several underwriters named in Schedule I thereto (the “Underwriters”), relating to an underwritten initial public offering (the “IPO”) of the Company’s units (the “Units”), each Unit comprised of one ordinary share, par value $0.0001 (the “Ordinary Shares”), and one-half of one warrant, each whole warrant exercisable for one Ordinary Share (each, a “Warrant”). Certain capitalized terms used herein are defined in paragraph 12 hereof.
Scilex Holding Company 5,882,353 Shares of Common Stock (par value $0.0001 per share) (the “Common Stock”) 5,882,353 Warrants to Purchase 5,882,353 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • March 5th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
Scilex Holding Company, a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 5,882,353 shares of its common stock, par value $0.0001 per share (the “Shares”, and the 5,882,353 Shares to be sold by the Company are called the “Firm Shares”) and (ii) an aggregate of warrants to purchase an aggregate of 5,882,353 shares of Common Stock, in the form set forth in Schedule B hereto, to purchase shares of Common Stock (the “Firm Warrants”). The Firm Shares, together with the Firm Warrants, are herein called the “Firm Securities.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 882,352 shares of Common Stock (the “Optional Shares”) and/or Common Warrants to purchase up to an aggregate of 882,352 shares of Common Stock (the “Optional Warrants,” and together with the Optional Shares, the “Optional Securiti
AGREEMENT AND PLAN OF MERGER dated as of August 30, 2024 by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc.Merger Agreement • September 9th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (the “Agreement”), dated as of August 30, 2024 (the “Signing Date”), is made and entered into by and among Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, “Parent”), Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
WARRANT AGREEMENTWarrant Agreement • January 11th, 2021 • Vickers Vantage Corp. I • Blank checks • New York
This WARRANT AGREEMENT (this “Agreement”) is made as of January 6, 2021 between Vickers Vantage Corp. I, a Cayman Islands exempted company, with offices at 1 Harbourfront Avenue, #16-06, Keppel Bay Tower, Singapore 098632 (“Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, with offices at 1 State Street, New York, New York 10004, as warrant agent (“Warrant Agent”).
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 17th, 2022 • Scilex Holding Company/De • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 10, 2022, is made and entered into by and among, (i) Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I (the “Company”), (ii) the equityholders designated as Sponsor Equityholders on Schedule A hereto (collectively, the “Sponsor Equityholders”); and (iii) Sorrento Therapeutics, Inc. (the “Legacy Scilex Equityholder” and, together with the Sponsor Equityholders and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, the “Holders” and each individually a “Holder”). Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
December 9, 2024 SCLX Stock Acquisition JVConsent Letter • December 10th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances)
STOCK PURCHASE AGREEMENT BY AND BETWEEN SCILEX HOLDING COMPANY AND SORRENTO THERAPEUTICS, INC. September 21, 2023Stock Purchase Agreement • September 26th, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
THIS STOCK PURCHASE AGREEMENT is made and entered into as of September 21, 2023 (this “Agreement”), by and between Scilex Holding Company, a Delaware corporation (the “Purchaser”) and Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”). Purchaser and the Seller are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENTAssignment, Assumption and Release Agreement • September 26th, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
THIS ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT (this “Agreement”) is executed on September 21, 2023 (the “Effective Date”), by and among Scilex Holding Company (“Scilex”), Oramed Pharmaceuticals Inc. (“Oramed”), Sorrento Therapeutics, Inc. (“Sorrento”), and Scintilla Pharmaceuticals, Inc. (together with Sorrento, the “Debtors”).
COMMON STOCK PURCHASE WARRANT SCILEX HOLDING COMPANYCommon Stock Purchase Warrant • December 13th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _______________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [December 11, 2029 / June 13, 2027]1 (the “Termination Date”), to subscribe for and purchase from Scilex Holding Company, a Delaware corporation (the “Company”), up to _____________ shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain engagement letter, dated as of March 22, 2024, by and between the Company and StockBlock Securities LLC.
SPONSOR INTEREST PURCHASE AGREEMENTSponsor Interest Purchase Agreement • September 9th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • Delaware
THIS SPONSOR INTEREST PURCHASE AGREEMENT, dated August 30, 2024 (this “Agreement”), is entered into by and between Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the “Sponsor”), and Scilex Holding Company, a Delaware corporation (the “Purchaser”).
CREDIT AND SECURITY AGREEMENT between SCILEX PHARMACEUTICALS INC.Credit and Security Agreement • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • Delaware
This CREDIT AND SECURITY AGREEMENT (this “Agreement”) dated as of December 14, 2020, is entered into between SCILEX PHARMACEUTICALS INC., a Delaware corporation (“Borrower”), and CNH FINANCE FUND I, L.P., a Delaware limited partnership (the “Lender”).
SCILEX HOLDING COMPANY SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • November 14th, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • California
This Severance and Change in Control Agreement (the “Agreement”) is made and entered into by and between Henry Ji (“Executive”) and Scilex Holding Company, a Delaware corporation (the “Company”), effective as of November 9, 2023 (the “Effective Date”).
STOCKHOLDER AGREEMENTStockholder Agreement • September 14th, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • Delaware
THIS STOCKHOLDER AGREEMENT (this “Agreement”), dated as of September 12 2022, is made and entered into by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, the “Company”), and Sorrento Therapeutics, Inc., a Delaware corporation (“Stockholder”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 21st, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 21, 2023, is between SCILEX HOLDING COMPANY, a company incorporated under the laws of the State of Delaware (the “Company”), and the investor listed on the Schedule of Buyers attached as Schedule I hereto (the “Buyer”).
CONSENT UNDER AND AMENDMENT NO. 4 TO INDENTUREIndenture • July 21st, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • New York
This CONSENT UNDER AND AMENDMENT NO. 4 TO INDENTURE is entered into as of June 2, 2022 (this “Amendment”) by and among SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Issuer”), SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Parent Guarantor”), U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (as successor in interest to U.S. Bank National Association), as trustee (in such capacity, together with its successors and assigns in such capacity, the “Trustee”) and collateral agent (in such capacity, together with its successors and assigns in such capacity, the “Collateral Agent”) under the Indenture (as defined below), and the beneficial owners of the Securities and the Holders listed on the signature pages hereof (collectively, the “Holders”).
STOCKHOLDER AGREEMENTStockholder Agreement • September 3rd, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • Delaware
THIS STOCKHOLDER AGREEMENT (this “Agreement”), dated as of August 30, 2024, is made and entered into by and between Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, the “Company”), and Scilex Holding Company, a Delaware corporation (“Stockholder”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
COMPANY STOCKHOLDER SUPPORT AGREEMENTCompany Stockholder Support Agreement • September 3rd, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances)
This COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of August 30, 2024 (this “Support Agreement”), is entered into by and among the Stockholders listed on Exhibit A hereto (each, a “Stockholder” and collectively, the “Stockholders”), Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing) (“Parent”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
SETTLEMENT AGREEMENT AND MUTUAL RELEASESSettlement Agreement • May 13th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • Delaware
This Settlement Agreement and Mutual Releases (the “Agreement”) is entered into as of February 29, 2024 by and among Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc., on the one hand, and Virpax Pharmaceuticals, Inc. on the other hand. They are collectively referred to herein as “the Parties” and each individually as a “Party.”
October 8, 2024 Scilex Holding CompanySenior Secured Promissory Note • October 8th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances)
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 26th, 2023 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 21, 2023, between Scilex Holding Company, a Delaware corporation (the “Company”), Oramed Pharmaceuticals, Inc., a Delaware corporation as the initial purchaser (the “Initial Purchaser”), and the Agent.
